Literature DB >> 33631410

Efficacy of dupilumab in patients with aspirin-exacerbated respiratory disease and previous inadequate response to anti-IL-5 or anti-IL-5Rα in a real-world setting.

Nicole Bavaro1, Deborah Gakpo2, Anisha Mittal2, Jillian C Bensko2, Tanya M Laidlaw3, Kathleen M Buchheit4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33631410      PMCID： PMC8277677          DOI： 10.1016/j.jaip.2021.02.020

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


× No keyword cloud information.
  9 in total

1.  Aspirin-Exacerbated Respiratory Disease--New Prime Suspects.

Authors:  Tanya M Laidlaw; Joshua A Boyce
Journal:  N Engl J Med       Date:  2016-02-04       Impact factor: 91.245

2.  Diagnosis and management of NSAID-Exacerbated Respiratory Disease (N-ERD)-a EAACI position paper.

Authors:  Marek L Kowalski; Ioana Agache; Sevim Bavbek; Arzu Bakirtas; Miguel Blanca; Grażyna Bochenek; Matteo Bonini; Enrico Heffler; Ludger Klimek; Tanya M Laidlaw; Joaquim Mullol; Ewa Niżankowska-Mogilnicka; Hae-Sim Park; Marek Sanak; Mario Sanchez-Borges; Silvia Sanchez-Garcia; Glenis Scadding; Masami Taniguchi; Maria J Torres; Andrew A White; Aleksandra Wardzyńska
Journal:  Allergy       Date:  2018-10-02       Impact factor: 13.146

3.  Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD.

Authors:  Tanya M Laidlaw; Joaquim Mullol; Chunpeng Fan; Donghui Zhang; Nikhil Amin; Asif Khan; Jingdong Chao; Leda P Mannent
Journal:  J Allergy Clin Immunol Pract       Date:  2019-04-04

4.  Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma.

Authors:  Parameswaran Nair; Sally Wenzel; Klaus F Rabe; Arnaud Bourdin; Njira L Lugogo; Piotr Kuna; Peter Barker; Stephanie Sproule; Sandhia Ponnarambil; Mitchell Goldman
Journal:  N Engl J Med       Date:  2017-05-22       Impact factor: 91.245

5.  Disconnect between effects of mepolizumab on severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps.

Authors:  Rory Chan; Chris RuiWen Kuo; Brian Lipworth
Journal:  J Allergy Clin Immunol Pract       Date:  2020-01-15

6.  A retrospective analysis of mepolizumab in subjects with aspirin-exacerbated respiratory disease.

Authors:  Katherine L Tuttle; Kathleen M Buchheit; Tanya M Laidlaw; Katherine N Cahill
Journal:  J Allergy Clin Immunol Pract       Date:  2018-03-06

7.  Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.

Authors:  Mario Castro; Jonathan Corren; Ian D Pavord; Jorge Maspero; Sally Wenzel; Klaus F Rabe; William W Busse; Linda Ford; Lawrence Sher; J Mark FitzGerald; Constance Katelaris; Yuji Tohda; Bingzhi Zhang; Heribert Staudinger; Gianluca Pirozzi; Nikhil Amin; Marcella Ruddy; Bolanle Akinlade; Asif Khan; Jingdong Chao; Renata Martincova; Neil M H Graham; Jennifer D Hamilton; Brian N Swanson; Neil Stahl; George D Yancopoulos; Ariel Teper
Journal:  N Engl J Med       Date:  2018-05-21       Impact factor: 91.245

8.  Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.

Authors:  Claus Bachert; Joseph K Han; Martin Desrosiers; Peter W Hellings; Nikhil Amin; Stella E Lee; Joaquim Mullol; Leon S Greos; John V Bosso; Tanya M Laidlaw; Anders U Cervin; Jorge F Maspero; Claire Hopkins; Heidi Olze; G Walter Canonica; Pierluigi Paggiaro; Seong H Cho; Wytske J Fokkens; Shigeharu Fujieda; Mei Zhang; Xin Lu; Chunpeng Fan; Steven Draikiwicz; Siddhesh A Kamat; Asif Khan; Gianluca Pirozzi; Naimish Patel; Neil M H Graham; Marcella Ruddy; Heribert Staudinger; David Weinreich; Neil Stahl; George D Yancopoulos; Leda P Mannent
Journal:  Lancet       Date:  2019-09-19       Impact factor: 79.321

9.  Mepolizumab treatment in patients with severe eosinophilic asthma.

Authors:  Hector G Ortega; Mark C Liu; Ian D Pavord; Guy G Brusselle; J Mark FitzGerald; Alfredo Chetta; Marc Humbert; Lynn E Katz; Oliver N Keene; Steven W Yancey; Pascal Chanez
Journal:  N Engl J Med       Date:  2014-09-08       Impact factor: 91.245
  9 in total
  5 in total

1.  Dupilumab-associated arthralgia in patients with aspirin-exacerbated respiratory disease.

Authors:  Lorena Miss Ozuna; Tessa Ryan; Jillian C Bensko; Tanya M Laidlaw; Kathleen M Buchheit
Journal:  Ann Allergy Asthma Immunol       Date:  2022-02-03       Impact factor: 6.347

Review 2.  New concepts for the pathogenesis and management of aspirin-exacerbated respiratory disease.

Authors:  Esha Sehanobish; Mohammad Asad; Elina Jerschow
Journal:  Curr Opin Allergy Clin Immunol       Date:  2022-02-01

3.  Aspirin desensitization and biologics in aspirin-exacerbated respiratory disease: Efficacy, tolerability, and patient experience.

Authors:  Jyotsna Mullur; Camille M Steger; Deborah Gakpo; Jillian C Bensko; Rie Maurer; Tanya M Laidlaw; Kathleen M Buchheit
Journal:  Ann Allergy Asthma Immunol       Date:  2022-02-05       Impact factor: 6.248

4.  Rapid and sustained effect of dupilumab on clinical and mechanistic outcomes in aspirin-exacerbated respiratory disease.

Authors:  Kathleen M Buchheit; Aaqib Sohail; Jonathan Hacker; Rie Maurer; Deborah Gakpo; Jillian C Bensko; Faith Taliaferro; Jose Ordovas-Montanes; Tanya M Laidlaw
Journal:  J Allergy Clin Immunol       Date:  2022-04-20       Impact factor: 14.290

5.  Immunology-based recommendations for available and upcoming biologics in aspirin-exacerbated respiratory disease.

Authors:  Kathleen M Buchheit; Tanya M Laidlaw; Joshua M Levy
Journal:  J Allergy Clin Immunol       Date:  2021-06-23       Impact factor: 14.290
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.